Sthree Share Discussion Threads

[don muang] 21/12/2006 15:31

andrbea .... STEM seems to b one to buy and hold ... (or accumulate and hold) .... very positive medium/long term and it's not caught up in any biotech bubble yet .... no doubt this sector will be a flavour of the month before too long...

[don muang] 14/12/2006 09:20

interesting non-reg announcement concerning 'stategic appointmmt'.

[dave-w] 07/12/2006 22:09

And another ha'penny today! Anybody know why the mm's might be interested in acquiring some stem stock?

[dave-w] 06/12/2006 16:57

No RNS, no press release, one 50,000 sell... and the share price jumps up a whole penny??? Wonder what's going round the MM's rumour mill?

[don muang] 15/11/2006 18:53

A stem cell breakthrough could lead to a treatment for muscular dystrophy (MD), research has revealed.

[don muang] 14/11/2006 16:27

A malfunctioning heart could be restored to health with the help of stem cells ....

[dave-w] 14/11/2006 15:21

Yes, alot of fairly good spadework providing what seems to be a sound foundation. But realistically the delayed revenue stream will inevitably seriously impede the share price
As Don says, the aussie mkt may prove to be a more fruitful source of funds as and when required... but it can also bite off the hand of beggars!
Methinks next May might be an interesting time one way or the other.

[don muang] 08/11/2006 07:34

Item on the first project to be funded by the UK Stem Cell Foundation

Stem cell jabs for heart patients

[don muang] 02/11/2006 08:33

think the PI interest in it is non-existant. assume 'interested' larger holders bought in to it pre-float.

I'm fairly positive on it. It's in a specialist niche market. It's making agreements with reputable organisations and large companies.

Now that share price seems to have stabilized post-IPO then guess it'll burble along at similar levels until a major announcement sends it swiftly up. Downside is future fundraising. However, that looks like it'll be done in a more 'appreciative' market (Australia). Most of that downside I presume is already factored in though.

Just my 2p's worth.

(If you think this has a low trading profile then VTO is even 'worse' - positive announcements with that don't get any buys - or sells !!!).

[aldi1] 02/11/2006 08:25

this seems like a positive rns, but nobody seems to have noticed(1 buy so far).

any views?

[don muang] 02/11/2006 07:20

Collaboration with REMEDI

RNS Number:4118L
Stem Cell Sciences plc
02 November 2006


Embargoed until 07.00 2 November 2006

Stem Cell Sciences plc

("Stem Cell Sciences", "SCS" or "the Group")

Stem Cell Sciences' NS Cells to begin Preclinical Trials for Spinal Cord Injury

Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on
the commercialisation of stem cells and stem cell technologies in research and
novel cell-based therapies, is pleased to announce that the Group's Neural Stem
Cells (NS cells) will enter preclinical testing for spinal cord injury in a
groundbreaking collaboration with the world-renowned Regenerative Medicine
Institute (REMEDI) at the National University of Ireland, Galway ("NUI Galway").

The initial study will examine the ability of the NS cells to provide functional
improvements in models of spinal cord injury at REMEDI.

Spinal cord injury affects more than 25 million people worldwide, with 130,000
new cases reported each year. It represents a considerable social and economic
cost to both families and countries.

"It's a really exciting opportunity for us to test our NS cells in preclinical
models of spinal cord injury" said SCS's Chief Scientific Officer, Dr Tim
Allsopp. "We will examine how the cells remain viable, engraft and support
natural repair processes. We are really pleased to be collaborating with NUI
Galway's Regenerative Medicine Institute".

Stem Cell Sciences' NS cells are unique in that they can be grown in serum-free
and feeder-free cell culture conditions. Potentially, this makes them very
effective when used in a variety of cell-based therapeutics.

Professor Frank Barry, REMEDI's Scientific Director and a world-leading
scientist in stem cell therapy, said: "For REMEDI to be able to evaluate a 'best
in class' neural stem cell in conjunction with a world-leading company is a
great opportunity for us, and underscores the efforts we are making in Ireland
in finding novel therapeutic solutions for currently incurable conditions."

Initial study results are expected in the first quarter of 2007. If this study
proves successful, Stem Cell Sciences and REMEDI plan to expand the
collaboration with more extensive testing.

"It would be a great step forward if we demonstrate efficacy for our NS cells in
this model" said Dr Peter Mountford, Chief Executive Officer of SCS. "With our
capabilities in novel cell culture media development and stem cell uses in drug
discovery, our next step was always to move into pre-clinical trials of illness
and disease, using the NS cells."

Dr Daniel O'Mahony, Director of Technology Transfer at NUI Galway said, "We are
bringing together two technology leaders in their respective fields in the
development of new treatments for spinal cord injury. This collaboration between
REMEDI and SCS reinforces our commitment to industrial collaborations and to
progressing technologies from the laboratory

[don muang] 25/10/2006 13:02

Regarding Millipore then note the Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide.

So this looks an interesting Licence Agreement with potential revenue this year. Presume release of RNS was at 12.00 BST to allow a similar one to be issued in the USA this morning.

[don muang] 25/10/2006 12:56

just some notes from todays RNS:

... it has signed an exclusive license agreement with Millipore Corporation to develop and market SCS' serum free media....

... the defined media will be the first product available in the industry that offers improved methods for growing hESCs without the need for animal serum...

... Millipore will manufacture, market and sell the new media under the brand name HEScGRO Embryonic Stem Cell Medium. SCS will receive royalties from all future sales ....

.... Millipore expects to have HEScGRO Embryonic Stem Cell Medium available for
commercial distribution before the end of the year....

[don muang] 25/10/2006 12:48

License Agreement

RNS Number:0148L
Stem Cell Sciences plc
25 October 2006

Embargoed until 12.00 GMT 25 October 2006

Stem Cell Sciences plc
("Stem Cell Sciences", "SCS" or "the Group")

Stem Cell Sciences Announce Agreement
to Provide Human Embryonic Stem Cell Media

Stem Cell Sciences plc (AIM:STEM), the global biotechnology company focused on
the commercialisation of stem cells and stem cell technologies in research and
novel cell-based therapies, is pleased to announce that it has signed an
exclusive license agreement with Millipore Corporation to develop and market
SCS' serum free media for the growth of human embryonic stem cells (hESCs). The
defined media will be the first product available in the industry that offers
improved methods for growing hESCs without the need for animal serum.

By eliminating the need for serum, researchers can generate improved
experimental results by avoiding interference from animal products in the media,
which will improve the ease of use and reliability in growing hESC's. The lack
of animal-free, defined media for growing hESCs has been an important technical
hurdle in enabling researchers to advance their understanding of the therapeutic
value of stem cells.

SCS Vice President and Chief Operating Officer, Hugh Ilyine said: "As
researchers investigate using stem cells to create cures for new diseases, the
use of hESCs are critical. By providing serum-free media to grow hESC's,
scientists can be confident that the effects they are studying in the laboratory
are from the cell itself and not from animal products in the media. The
expansion of our agreement with Millipore will allow researchers to now benefit
from products offering superior performance in both mouse and human stem cell
research."

Under the terms of the agreement, Millipore will manufacture, market and sell
the new media under the brand name HEScGRO Embryonic Stem Cell Medium. SCS will
receive royalties from all future sales of HEScGRO Embryonic Stem Cell Medium.
The agreement builds on the successful collaboration between Millipore and SCS
formed in 2005 to commercialize media for the growth of mouse embryonic cells.
Millipore's ESGRO Complete(TM)is the leading product used by researchers today
for mouse stem cell experimentation.

"Millipore is committed to being the most innovative supplier of products to the
stem cell research market," said Dominique Baly, President of Millipore's
Bioscience Division. "Our agreement with SCS reflects the significant
investments we are making to serve the needs of researchers exploring the
therapeutic value of stem cells. We chose SCS because their media worked
extremely well in growing hESCs in a variety of different stem cell lines and
conditions and they had the most advanced development of serum-free media."

Millipore expects to have HEScGRO Embryonic Stem Cell Medium available for
commercial distribution before the end of the year. HEScGRO has been shown to
be effective at growing many different human embryonic stem cell lines,
including lines that have been approved by the U.S. government for use in
federally sponsored research, as well as the "MEL" hES cell lines derived by
Stem Cell Sciences in Australia and distributed by Millipore. Millipore offers
a broad range of products and reagents for stem cell research through its
Chemicon product line, which is part of the company's Research Reagents Business
Unit.

Millipore Research Reagents Business Unit creates innovative and high quality
biological reagents for life science researchers to conduct their experiments
consistently. These biological reagents include antibodies, dyes and biochemical
reagents that are used to identify and measure cellular interactions, cell
signaling and other cellular functions.

- Ends

[don muang] 16/10/2006 10:41

not directly related to STEM, but an interesting article in The Independent' today entitled 'Stem cells could be used to revrse symptoms of motor neurone disease'.

[don muang] 06/10/2006 07:36

Notice of EGM

RNS Number:0582K
Stem Cell Sciences plc
06 October 2006



Embargoed until 0700 6 October 2006

Stem Cell Sciences plc

Notice of EGM re Possible Dual Listing

The Directors of Stem Cell Sciences PLC ("SCS") or (the "Company"), the
biotechnology company focused on the commercialisation of stem cells and stem
cell technologies, today announced they were intending to dual list the
Company's Ordinary Shares on the Australian Stock Exchange ("ASX") whilst
continuing to trade on the AIM market of the London Stock Exchange ("AIM").

In conjunction with a listing, which the Directors believe will improve
liquidity in the stock, the Company intends to raise additional funds to support
the continued growth of the business.

The Directors have convened an extraordinary general meeting of the shareholders
of the Company for 1 November 2006 to seek the approval of the shareholders to
proceed with the proposed dual listing on the ASX, fund raising, to approve the
share sub-division and for any other related matters.

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy ordinary shares in any jurisdiction.

- Ends -

[dave-w] 15/9/2006 15:02

Results out. Flat. Losses same as last. Some delays in installing plant will mean anticipated revenue stream will now not commence until 2007. share price little reaction.
Company says low share price will make raising of capital more difficult but what do they expect? Carts never move quickly with the horse behind!! Comment is rather naiive and a bit worrying. Fortunately cash situation looks to be reasonable still, given anticipated revenue schedule.

[don muang] 05/9/2006 20:38

Notice of Results

RNS Number:5323I
Stem Cell Sciences plc
05 September 2006


For Immediate Release 5 September 2006

Stem Cell Sciences plc

Notice of Interim Results

Stem Cell Sciences plc, the global stem cell company focused on the application
of stem cell technologies to cell culture media, cell based drug screens and
novel cell therapies, will be announcing interim results for the six months
ended 30 June 2006 on Friday 15 September 2006.

- Ends

[don muang] 04/9/2006 14:54

Interesting three paragraphs on this company in last weeks 'Shares' mag - the Collins Stuart analyst reacons a fair market cap for it is £74m. So that's over six times the present figure !! So fingers (and any other part of the anatomy) crossed.

[dave-w] 27/7/2006 10:39

You still watching this maestro? Beginning to look increasingly interesting. cash position is good, profitability predictions seem realistic. Mkt has ignored them. I picked up a few to lock away as with news such as below, it seems likely they won't go much lower.


LONDON (AFX) - Stem Cell Sciences PLC (SCS) has in-licensed a novel human stem cell, discovered in fat tissue and easily grown, which the company said could help to improve the drug discovery process.

The so-called 'human multi-potent adipocyte-derived stem cell' has been shown by scientists to be capable of producing fat and bone at very high efficiency, and will be suited for drug discovery in such areas as obesity and osteoporosis.

SCS holds world-wide exclusive rights to commercialise the cells for drug discovery in the field of obesity, and an exclusive option in the field of osteoporosis.

The company said the new licence will enable it to position itself as the leading supplier of stem cell derived cell types for drug discovery, a rapidly developing market.

'We have been delighted with the way these cells have performed and expect their addition to our cell-based screening platform will substantially expand the range of discovery assays that we can offer to pharmaceutical industry partners,' chief executive Dr Peter Mountford said in a statement.

Shares in AIM-listed Stem Cells closed Monday at 56.5 pence, valuing the company at 12.6 mln stg.

[maestro.] 05/9/2005 08:17

could be interesting!
RNS Number:8068Q
Stem Cell Sciences plc
05 September 2005

5 September 2005


Stem Cell Sciences - New Licence Deal with Deltagen


Stem Cell Sciences plc - the Edinburgh based stem cell research company - has
today announced a major licensing agreement with U.S.-based Deltagen, Inc. for
use of its patented IRES technology.


In addition to an up-front licence fee of U.S.$1.2 million, the agreement
includes royalties based on revenues generated by Deltagen. As part of the
deal, Stem Cell Sciences will receive from Deltagen selected genetically
engineered mice.


This announcement follows the recent listing of Stem Cell Sciences (STEM) on the
London Stock Exchange's Alternative Investment Market (AIM) and the subsequent
granting of expanded claims for a key patent in relation to Stem Cell Selection
in the US. The US is a major market in Stem Cell Sciences' expansion programme.
The Deltagen agreement and the awarding of the extended patent claims in the
US increases the base for future licensing deals in the important North American
market.


Deltagen becomes the first company licensed to use Stem Cell Sciences' IRES
technology for the manufacture, sale and sub-licensing of 'knock-out' mice. Dr
Peter Mountford, CEO of Stem Cell Sciences said; "We are very pleased to be
expanding our business in bio-medical research. The human stem cell field is
another exciting opportunity for the company and we are looking forward to
further licensing deals for our IRES technology in this sector."


Robert Driscoll, J.D., Ph.D., Vice President of Intellectual Property & Legal
Affairs for Deltagen, Inc. said; "The granting of this licence ensures our
ability to incorporate Stem Cell Sciences' powerful IRES technology into our
full product range of knockout mouse-related materials."